Results 21 to 30 of about 38,527 (248)

Drug delivery of carvedilol (cardiovascular drug) using phosphorene as a drug carrier: a DFT study

Journal of Taibah University for Science, 2022
2D nanomaterial phosphorene is a chemistically stable, biocompatible, and biodegradable drug delivery platform. This study investigates the drug loading efficiency of phosphorene for the cardiovascular drug carvedilol using density-functional theory (DFT)
Javeria Rafique, Qaba Qusain Afzal, Mehvish Perveen, Javed Iqbal, Mohammed Salim Akhter, Sidra Nazir, M. S. Al-Buriahi, Sultan Alomairy, Z. A. Alrowaili   +8 more
doaj   +1 more source

Development of Carvedilol-Loaded Albumin-Based Nanoparticles with Factorial Design to Optimize In Vitro and In Vivo Performance

Pharmaceutics, 2023
Carvedilol, an anti-hypertensive medication commonly prescribed by healthcare providers, falls under the BCS class II category due to its low-solubility and high-permeability characteristics, resulting in limited dissolution and low absorption when taken
Mohamed S. Attia, Mohamed F. Radwan, Tarek S. Ibrahim, Tarek M. Ibrahim   +3 more
doaj   +1 more source

COMPARATIVE CONTROLLED STUDY OF ANTIHYPERTENSIVE EFFICACY AND SAFETY OF CARVEDILOL IN PATIENTS WITH HYPERTENSION AND OBESITY OR DIABETES 2 TYPE (BASED ON RESULTS OF MULTICENTER TRIAL ACCORD)

Рациональная фармакотерапия в кардиологии, 2016
Aim. To study efficacy and safety of beta-blocker with vasodilating properties carvedilol (Acridilole, Akrihin, Russia) as a part of the combined therapy of patients with arterial hypertension (HT) and diabetes mellitus 2 type (DM2) and/or obesity ...
Yu. V. Yu.V. Lukina, S. Yu. Martsevich, A. D. Deev, S. A. Shalnova   +3 more
doaj   +3 more sources

COMPARISON OF THE METABOLIC EFFECTS OF CARVEDILOL AND METОPROLOL IN HYPERTENSIVE PATIENTS WITH OVERWEIGHT AND OBESITY. THE CAMELLIA TRIAL

Рациональная фармакотерапия в кардиологии, 2016
Aim. To compare two therapies based on carvedilol or metoprolol in hypertensive patients with overweight and obesity.Material and methods. 320 patients with arterial hypertension (1-2 degree) were involved in the study.
S. Y. Martsevich, N. P. Kutishenko, E. V. Shilova, A. D. Deev, S. A. Shalnova, R. G. Oganov, I. A. Veliganina, E. G. Volkova, Yu. E. Voskanjan, L. I. Gapon, P Ya. Dovgalevskij, V. Ya. Ermolina, E. M. Idrisova, N. N. Ilov, A. R. Kiselev, S. Yu. Levashov, V. A. Nevzorova, G. I. Nechaeva, T. N. Panova, I. I. Reznik, V. V. Skibickij, L. A. Sokolova, V. P. Terentev, N. V. Hailo, A. V. Shabalin, T. V. Shnjukova, V. V. Yakusevich   +26 more
doaj   +3 more sources

Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF) [PDF]

, 2014
Aim<p></p> To describe the baseline characteristics and treatment of the patients randomized in the PARADIGM-HF (Prospective comparison of ARNi with ACEi to Determine Impact on Global Mortality and morbidity in Heart Failure) trial, testing ...
Adel R. Rizkala, Akshay S Desai, Jean L. Rouleau, Jianjian Gong, John J. V. McMurray, Karl Swedberg, Martin Lefkowitz, Michael R. Zile, Milton Packer, null null, Scott D. Solomon, Victor C. Shi   +11 more
core   +3 more sources

Cardiopulmonary interactions with beta-blockers and inhaled therapy in COPD [PDF]

, 2017
Background: Beta-blockers remain underused in patients with COPD and cardiovascular disease. Aim: We compared how different inhaled therapies affect tolerability of bisoprolol and carvedilol in moderate to severe COPD.
Anderson, W., Jabbal, S., Lipworth, B. J., Manoharan, A., Morrison, A., Short, P.   +5 more
core   +2 more sources

Carvedilol

New England Journal of Medicine, 1999
Carvedilol is the first beta-blocker to obtain approval for treatment of heart failure. Improvement in hemodynamic parameters was initially documented in three methodologically sound studies involving 156 patients. Follow up was limited to 16 weeks. A placebo-controlled, double-blind trial involving 1094 patients showed beneficial effects on overall ...
  +7 more sources

Selecting the primary endpoint in a randomized clinical trial: the ARE method [PDF]

, 2016
The decision on the primary endpoint in a randomized clinical trial is of paramount importance and the combination of several endpoints might be a reasonable choice. Gómez and Lagakos (2013) have developed a method that quantifies how much more efficient
Gómez Melis, Guadalupe, Plana-Ripoll, Oleguer   +1 more
core   +2 more sources

Solubility enhancement of carvedilol by multicomponent crystal approach using glycine and arginine as coformers [PDF]

Pharmacia, 2023
A Carvedilol is a member of BCS class II, it has a low solubility and bioavailability. This work intends to increase the solubility of carvedilol using a multicomponent crystal method.
Iyan Sopyan, Wuri Ariestika Sari, Sandra Megantara, Taofik Rusdiana   +3 more
doaj   +3 more sources

Effect on Mortality of Higher Versus Lower β-Blocker (Metoprolol Succinate or Carvedilol) Dose in Patients With Heart Failure [PDF]

, 2018
This study aimed to compare the effect of β-blocker dose and heart rate (HR) on mortality in patients with heart failure with reduced ejection fraction (HFrEF).
Ajam, Samer, Ajam, Tarek, Devaraj, Srikant, Fudim, Marat, Kamalesh, Masoor   +4 more
core   +1 more source